<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580994</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1417-LCG</org_study_id>
    <secondary_id>2014-003090-42</secondary_id>
    <nct_id>NCT02580994</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Untreated Extensive SCLC</brief_title>
  <acronym>REACTION</acronym>
  <official_title>REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, two armed, controlled, and randomized phase II trial&#xD;
      investigating the activity of pembrolizumab in combination with standard chemotherapy in&#xD;
      Extensive Disease (ED)-SCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, two armed, controlled, and randomized phase II trial&#xD;
      investigating the activity of pembrolizumab in combination with standard chemotherapy in&#xD;
      ED-SCLC.&#xD;
&#xD;
      Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the&#xD;
      informed consent, and then centrally randomized 1:1 to the experimental arm (Arm A) and the&#xD;
      control arm (Arm B).&#xD;
&#xD;
      Cross-over at the time of disease progression will be allowed for arm B only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 8, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">September 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Small Cell Lung Cancer (SCLC)</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles of cis/carboplatin and etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion at the dose of 200 mg on day 1 every 3 weeks</description>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cis/carboplatin and etoposide</intervention_name>
    <description>Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <other_name>Platinol, Paraplatin and Etopophos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed SCLC&#xD;
&#xD;
          -  Extended disease according to the criteria of the Veteran's Administration - Lung&#xD;
             Cancer Group (VALG): disease extended beyond a hemithorax and the supraclavicular node&#xD;
             area. Pleural involvement will be considered as extended disease&#xD;
&#xD;
          -  Assessment of adequate tissue availability for Program Cell Death-Ligand 1 (PD-L1)&#xD;
             immunohistochemistry testing&#xD;
&#xD;
          -  Before patient registration, written informed consent must be given according to&#xD;
             International Conference of Harmonization-Good Clinical Practice (ICH-GCP), and&#xD;
             national/local regulations&#xD;
&#xD;
          -  Tumor assessment performed within 10 days before randomization. Patient may or may not&#xD;
             have measurable disease&#xD;
&#xD;
          -  Previous palliative brain radiotherapy is allowed if terminated at least 3 weeks&#xD;
             before randomization&#xD;
&#xD;
          -  Partial or complete response according to RECIST (Response Evaluation Criteria in&#xD;
             Solid Tumors) 1.1 after 2 cycles of any platinum-based induction chemotherapy regimen&#xD;
&#xD;
          -  Adequate hematopoietic, hepatic and renal function within 10 days before randomization&#xD;
             defined as follows:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10E9/L, Hemoglobin (Hb) ≥ 9 g/dL and&#xD;
                  platelet count ≥ 100 x 10E9/L&#xD;
&#xD;
               -  Serum creatinine clearance ≥ 60 mL/min as calculated with Cockcroft-Gault formula&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x Upper Limit Normal (ULN), Alanine Aminotransferase (ALT) (SGTP)&#xD;
                  and Aspartate Transaminase (AST) (SGOT) ≤ 3 x ULN&#xD;
&#xD;
               -  International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 x ULN unless&#xD;
                  subject is receiving anticoagulant therapy as long as PT or PTT is within&#xD;
                  therapeutic range of intended use of anticoagulants&#xD;
&#xD;
               -  Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN unless subject is&#xD;
                  receiving anticoagulant therapy as long as a PTT is within therapeutic range of&#xD;
                  intended use of anticoagulants N.B. Lactate Dehydrogenase (LDH) level assessment&#xD;
                  is mandatory for randomization&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must have a negative urine or serum pregnancy&#xD;
             test within 72 hours before randomization&#xD;
&#xD;
          -  Patients of childbearing / reproductive potential should use adequate birth control&#xD;
             measures, as defined by investigator, during the study treatment period and for at&#xD;
             least 120 days after the last study treatment. A highly effective method of birth&#xD;
             control is defined as those which result in low failure rate (i.e. less than 1% per&#xD;
             year) when used consistently and correctly.&#xD;
&#xD;
          -  Female subjects who are breast feeding should discontinue nursing before randomization&#xD;
             and until 120 days after the last study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy for SCLC; previous treatment with platinum and etoposide&#xD;
             concomitant with radiotherapy (RT) for limited disease is allowed if terminated at&#xD;
             least 1 year before patient randomization&#xD;
&#xD;
          -  known active central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
             Patients with previously treated brain metastases may participate provided they are&#xD;
             stable (i.e. without evidence of progression by imaging and any neurologic symptoms&#xD;
             have returned to baseline), have no evidence of new or enlarging brain metastases, and&#xD;
             have not received steroids for at least 7 days before randomization&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 3-4 (at&#xD;
             registration) (patients who are judged by the investigator to be PS 2 due to primary&#xD;
             disease are the only PS 2 patients who are eligible)&#xD;
&#xD;
          -  ECOG PS 2-4 (at randomization)&#xD;
&#xD;
          -  Less than 3 month life expectancy&#xD;
&#xD;
          -  History of interstitial lung disease (ILD) or a history of (non-infectious)&#xD;
             pneumonitis that required oral or IV steroids (other than Chronic Obstructive&#xD;
             Pulmonary Disease [COPD] exacerbation) or current pneumonitis or current evidence of&#xD;
             ILD&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.&#xD;
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs), any&#xD;
             replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment and is allowed&#xD;
&#xD;
          -  Previous allogeneic tissue/solid organ transplant&#xD;
&#xD;
          -  Active infection requiring therapy&#xD;
&#xD;
          -  Known history of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies&#xD;
             positive). No known active Hepatitis B or C. Active Hepatitis B is defined as a known&#xD;
             positive HBsAg results. Active Hepatitis C is defined by a known positive Hep C Ab&#xD;
             result and known quantitative Hepatitis C Virus (HCV) RNA results greater than the&#xD;
             lower limits of detection of the assay&#xD;
&#xD;
          -  Ongoing grade ≥ 2 peripheral neuropathy&#xD;
&#xD;
          -  Prior treatment with platinum, anti-PD-1, anti-PD-L1/2, anti interleukin-7&#xD;
             receptor-alpha (anti-CD127), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) modulators&#xD;
&#xD;
          -  Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in&#xD;
             the 3 days before randomization:&#xD;
&#xD;
          -  Corticosteroid use on study for management of pembrolizumab Events of Clinical&#xD;
             Interest (ECIs), as pre-medication for the administration of chemotherapies, and/or a&#xD;
             pre-medication for contrast allergies/reactions is allowed&#xD;
&#xD;
          -  Daily prednisone at doses of 5-7.5 mg is allowed as an example of replacement therapy.&#xD;
             Equivalent hydrocortisone doses are also permitted if administered as a replacement&#xD;
             therapy&#xD;
&#xD;
          -  Prior use of live vaccines within 30 days before randomization. Examples of live&#xD;
             vaccines include, but are not limited to, the following : measles, mumps, rubella,&#xD;
             chicken pox, shingles, yellow fever, influenza A virus subtype (H1N1) flu, rabies,&#xD;
             Bacillus Calmette-Guerin (BCG), and typhoid vaccine&#xD;
&#xD;
          -  Presence of any clinical, psychological, familial, sociological or geographical&#xD;
             condition potentially hampering compliance with the study protocol and follow-up&#xD;
             schedule; those conditions should be discussed with the patient before registration in&#xD;
             the trial&#xD;
&#xD;
          -  Concurrent treatment with any investigational agent within 4 weeks before&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Besse, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Menis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Oncologico Veneto IRCCS, Padova, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Faculty of Medicine - Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11331</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Avignon - Hopital Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopitalier Intercommunal De Creteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille - Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Annecy</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Paris - Hopital Avicenne</name>
      <address>
        <city>Paris</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cannizzaro</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Croce e Carle General Hospital</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Luigi Gonzaga - Universita Di Torino</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Santa Maria della Misericordia&quot; di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust - Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Sutton, Surrey</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extended Disease Small Cell Lung Cancer</keyword>
  <keyword>phase II</keyword>
  <keyword>randomized</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>cross-over</keyword>
  <keyword>etoposide</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>rechallenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

